Pomegranate Juice and Metabolic Syndrome
Not Applicable
Completed
- Conditions
- Metabolic Syndrome
- Interventions
- Other: pomegranate juiceOther: placebo
- Registration Number
- NCT02298621
- Lead Sponsor
- Urmia University of Medical Sciences
- Brief Summary
The effect of pomegranate juice (PJ) intake on cardiovascular risks in subject with metabolic syndrome.
- Detailed Description
The effect of pomegranate juice (PJ) intake on cardiovascular risks in subject with metabolic syndrome in shabestar.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
-
presence of ≥3 of the following diagnostic of MetS:
- serum TGs of at least 150 mg/dL,
- waist circumference of more than 102 cm (40 in) in men and more than 88 cm (35 in) in women,
- high-density lipoprotein (HDL) level less than 40 mg/dL in men and less than 50 mg/dL in women,
- blood pressure 135/85 mm Hg or higher, or
- fasting glucose 100 mg/dL or Higher
Read More
Exclusion Criteria
- liver cirrhosis,
- chronic pancreatitis,
- gastrointestinal or connective diseases,
- kidney stones, or
- renal failure,
- alcohol Consumption,
- having an allergy to pomegranate juice,
- a change in diet,
- the large increase in LDL so that required drug treatment.
- use of statins of fibrates, corticosteroids, nitrates, acetyl-salicylic acid or other anti-platelet drugs, oral hypoglycemic drugs, nonsteroidal anti-inflammatory drugs, or drugs interfering with coagulation;
- pregnancy or lactation in the past 6 mo, supplementation with vitamins or antioxidants
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description pomegranate juice placebo pomegranate juice: 500 ml placebo placebo sugar + aroma+ color: 500ml pomegranate juice pomegranate juice pomegranate juice: 500 ml placebo pomegranate juice sugar + aroma+ color: 500ml
- Primary Outcome Measures
Name Time Method Change from baseline in values of metabolic syndrome components at 1 week 1 week
- Secondary Outcome Measures
Name Time Method Change from baseline in values of insulin resistance (HOMA-IR), total cholesterol, LDL-C, VLDL-C and hs-CRP at 1 week 1 weeks Insulin resistance via HOMA-IR
Trial Locations
- Locations (1)
Urmia University of Medical Sciences
🇮🇷Urmia, Iran, Islamic Republic of